Core Viewpoint - The company has decided not to adjust the conversion price of its convertible bonds, despite triggering the downward adjustment clause due to stock price performance [2][7]. Group 1: Convertible Bond Details - The company issued 4.4 million convertible bonds at a face value of 100 RMB each, raising a total of 440 million RMB [3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and further adjusted to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025 [4]. - The downward adjustment clause is triggered when the stock price is below 85% of the conversion price for at least 15 out of 30 consecutive trading days [5]. Group 2: Board Decision - The board of directors convened on August 1, 2025, and unanimously agreed not to adjust the conversion price, with all related directors abstaining from the vote [8][9]. - The decision will remain in effect for three months, until November 1, 2025, during which time the company will not propose any downward adjustment even if the clause is triggered again [7][9].

Group 1 - The company held its 22nd meeting of the 4th Board of Directors on August 1, 2025, with all 7 participating directors voting unanimously [1] - The Board approved the proposal not to lower the conversion price of the "Jietai Convertible Bonds," with 4 votes in favor and no opposition or abstentions [1] - Related directors recused themselves from the voting process [1] Group 2 - The company will not propose a downward adjustment to the conversion price within the next three months, from now until November 1, 2025 [2] - If the conversion price adjustment clause is triggered again after November 2, 2025, the Board will reconvene to decide on the adjustment [2] - Further details are available in the announcement published on the Shanghai Stock Exchange website [2]

Core Viewpoint - The company, JieTe Bio, announced that its board of directors has approved a proposal not to lower the conversion price of its convertible bonds, known as "JieTe Convertible Bonds" [2] Group 1 - The fourth meeting of the fourth board of directors took place on August 1, where the proposal was reviewed and approved [2]

Core Points - Jiet Bio (688026) closed at 15.86 yuan on June 27, 2025, up 5.17% from the previous week's 15.08 yuan [1] - The company's total market capitalization is 2.226 billion yuan, ranking 116th out of 126 in the medical device sector and 4825th out of 5151 in the A-share market [1] Company Announcements - Jiet Bio announced the interest payment for "Jiet Convertible Bonds" for the year 2025, with a face value of 100 yuan per bond and an interest amount of 1.00 yuan (including tax) [1] - The bond interest record date is June 27, 2025, with the ex-dividend date and payment date set for June 30, 2025 [1] - The company issued 4.4 million convertible bonds in June 2022, raising a total of 440 million yuan, with a six-year term and an increasing interest rate, reaching 1.00% in the third year [1] - The interest payment for this period covers from June 28, 2024, to June 27, 2025, with a net interest distribution of 0.80 yuan after a 20% personal income tax [1]

Group 1 - The company's credit rating remains at A+ with a stable outlook for both the company and its convertible bonds [1][2] - The credit rating agency Zhongzheng Pengyuan conducted a follow-up credit rating for the company on June 26, 2025, confirming the ratings [2] - The previous credit rating was also A+ with a stable outlook, assessed on June 26, 2024 [1][2] Group 2 - The follow-up rating report was published on the Shanghai Stock Exchange website on the same day as the rating [2]

Core Viewpoint - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of the 2024 annual profit distribution plan, which includes a cash dividend of 0.73 yuan per 10 shares [1][2][4]. Summary by Sections Announcement of Adjustment - The conversion price of "洁特转债" will be adjusted from 48.02 yuan per share to 47.95 yuan per share, effective from July 2, 2025 [1][4]. - The trading of "洁特转债" will be suspended from June 24, 2025, until the equity registration date of July 1, 2025, and will resume on July 2, 2025 [1][4]. Basis for Adjustment - The adjustment is based on the resolution passed at the 2024 annual general meeting, which approved a cash dividend distribution of 0.73 yuan per 10 shares, with no stock increases or bonus shares [1][2][4]. - The total number of shares after excluding repurchased shares is 140,363,220, with 2,730,914 shares repurchased [4]. Calculation of Adjustment - The cash dividend per share is calculated as approximately 0.0716 yuan, leading to the new conversion price being calculated as follows: P1 = P0 - D, where P0 is the old conversion price and D is the cash dividend [4]. - The formula for adjusting the conversion price is provided, detailing how various corporate actions affect the conversion price [2][4]. Other Information - Investors seeking more details about "洁特转债" can refer to the company's prospectus published on June 24, 2022 [5].

证券代码：688026 证券简称：洁特生物 公告编号：2025-035 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 关于"洁特转债"2025 年付息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 可转债付息债权登记日：2025 年 6 月 27 日 ? 可转债除息日：2025 年 6 月 30 日（因 2025 年 6 月 28 日为非交易日， 除息日顺延至 2025 年 6 月 30 日） ? 可转债兑息日：2025 年 6 月 30 日（因 2025 年 6 月 28 日为非交易日， 兑息日顺延至 2025 年 6 月 30 日） 广州洁特生物过滤股份有限公司（以下简称"公司"）于 2022 年 6 月 28 日 发行的可转换公司债券将于 2025 年 6 月 30 日开始支付自 2024 年 6 月 28 日至 特定对象发行可转换公司债券募集说明书》 （以下简称"《募集说明书》"）有关条 款的规定，现将有关事项公告如下： 一、可转债发行上市概况 二、本次付息方 ...

Group 1 - The company will implement a cash dividend distribution of 0.73 yuan per 10 shares, totaling approximately 10.05 million yuan, which represents 13.92% of the net profit attributable to shareholders [1][2] - The company's total share capital is 140,363,220 shares, with 2,730,914 shares repurchased, affecting the calculation of the dividend distribution [1][2] - The dividend distribution plan was approved at the annual shareholders' meeting on May 7, 2025, and further details can be found in the announcement dated April 16, 2025 [1][2] Group 2 - The convertible bonds will undergo a price adjustment in accordance with the terms outlined in the bond issuance prospectus following the dividend distribution [2] - The trading of the convertible bonds will be suspended from June 24, 2025, until the registration date for the dividend distribution, with resumption of trading on the first trading day after the registration date [2] - Investors interested in the details of the convertible bonds can refer to the prospectus disclosed on June 24, 2022 [2]

Group 1 - The company will suspend the conversion of its convertible bonds from June 24, 2025, until the equity distribution record date, with conversion resuming on the first trading day after the record date [1] - The cash dividend plan for the fiscal year 2024 includes a distribution of 0.73 yuan (tax included) for every 10 shares held, amounting to a total cash dividend of 10.0472 million yuan (tax included) [1]

证券代码：688026 证券简称：洁特生物 公告编号：2025-010 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 第四届董事会第十七次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）第四届董事会第十七次会议于2025年4月11日以现 场及通讯相结合方式召开，会议通知已于2025年4月3日通过通讯方式送达全体董事。本次会议由董事长 袁建华先生召集并主持，应参加董事7人，实际参加表决董事7人。本次会议的召集、召开和表决程序均 符合国家有关法律、法规及《公司章程》等有关规定。经全体董事一致同意，形成决议如下： 一、以4票同意，0票反对，0票弃权，审议通过了《关于不向下修正"洁特转债"转股价格的议案》，关 联董事袁建华、Yuan Ye James、Dannie Yuan回避表决。 董事会同意本次不向下修正转股价格，同时在未来三个月内（即日起至2025年7月11日）如再次触发可 转换公司债券转股价格向下修正条款的，亦不提出向下修正方案。在此期 ...